Medivir Ab Aktie - 0GP7

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

41,70

Gebot

0,00

Fragen

0,00

Volumen

0,00

0,00 Tagesbereich 0,00

41,70 52-Wochen-Bereich 41,70

Marktkapitalisierung

4,394B

Handelsende

41,70

Handelsbeginn

Letzte Trade

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

1.026

Ausgegebene Aktien

105.371.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-49,19

Gewinn pro Aktie (EPS)

-0,85

Erlöse

7,66M

Nettogewinn

-89,32M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Diversified

Website

www.medivir.se

Hauptsitz

Huddinge, Swe

Gegründet

1992

Medivir Ab is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0GP7. The last closing price for Medivir Ab was SEK41,70. Over the last year, Medivir Ab shares have traded in a share price range of SEK 41,70 to SEK 41,70.

Medivir Ab currently has 105.371.000 shares in issue. The market capitalisation of Medivir Ab is SEK4,39 billion. Medivir Ab has a price to earnings ratio (PE ratio) of -49.19.

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox PR Newswire STOCKHOLM, Jan. 15, 2024 STOCKHOLM, Jan. 15, 2024...

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study PR Newswire STOCKHOLM, Jan. 4, 2024 STOCKHOLM, Jan. 4, 2024...

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan PR Newswire STOCKHOLM, Dec. 19, 2023 Sustained disease control...

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval PR Newswire STOCKHOLM, Dec. 13, 2023 STOCKHOLM...

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway PR Newswire STOCKHOLM, Dec. 6, 2023 STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB...

Medivir to present at the Carlsquare Equity Research Investor Day

Medivir to present at the Carlsquare Equity Research Investor Day PR Newswire STOCKHOLM, Dec. 6, 2023 STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical...

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Bulletin from Extraordinary General Meeting in Medivir AB (publ) PR Newswire STOCKHOLM, Dec. 1, 2023 STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the...

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC PR Newswire STOCKHOLM, Nov. 27, 2023 STOCKHOLM, Nov. 27...

Medivir to present at the Redeye Life Science Day

Medivir to present at the Redeye Life Science Day PR Newswire STOCKHOLM, Nov. 22, 2023 STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company...

Medivir to present at the Erik Penser Bank Company Event

Medivir to present at the Erik Penser Bank Company Event PR Newswire STOCKHOLM, Nov. 21, 2023 STOCKHOLM, Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	41.7	41.7	41.7	3434	41.7	DE
4	41.7	41.7	41.7	1726	41.7	DE
12	41.7	41.7	41.7	1026	41.7	DE
26	41.7	41.7	41.7	465	41.7	DE
52	41.7	41.7	41.7	280	41.7	DE
156	41.7	41.7	41.7	127	41.7	DE
260	41.7	41.7	41.7	299	41.7	DE

0GP7 - Frequently Asked Questions (FAQ)

What is the current Medivir Ab share price?

The current share price of Medivir Ab is SEK 41,70

How many Medivir Ab shares are in issue?

Medivir Ab has 105.371.000 shares in issue

What is the market cap of Medivir Ab?

The market capitalisation of Medivir Ab is SEK 4,39B

What is the 1 year trading range for Medivir Ab share price?

Medivir Ab has traded in the range of SEK 41,70 to SEK 41,70 during the past year

What is the PE ratio of Medivir Ab?

The price to earnings ratio of Medivir Ab is -49,19

What is the cash to sales ratio of Medivir Ab?

The cash to sales ratio of Medivir Ab is 573,59

What is the reporting currency for Medivir Ab?

Medivir Ab reports financial results in SEK

What is the latest annual turnover for Medivir Ab?

The latest annual turnover of Medivir Ab is SEK 7,66M

What is the latest annual profit for Medivir Ab?

The latest annual profit of Medivir Ab is SEK -89,32M

What is the registered address of Medivir Ab?

The registered address for Medivir Ab is LUNASTIGEN 5, 2ND FLOOR, PO BOX 1086, HUDDINGE, SE-141 22

What is the Medivir Ab website address?

The website address for Medivir Ab is www.medivir.se

Which industry sector does Medivir Ab operate in?

Medivir Ab operates in the PHARMACEUTICAL DIVERSIFIED sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WSLWorldsec Ld	2,00p (60,00%)	105,37k
BLUBlue Star Capital Plc	12,00p (45,45%)	1,54M
NTQEnteq Technologies Plc	1,40p (40,00%)	19,81M
BANKFiinu Plc	10,25p (36,67%)	12,95M
TIRTiger Royalties And Investments Plc	0,16p (28,00%)	139,07M
PODPPod Point Group Holdings Plc	10,88p (-35,20%)	6,83M
PALMPanther Metals Plc	53,50p (-35,15%)	226,06k
NOGNostrum Oil & Gas Plc	2,51p (-23,82%)	117,6k
ADMEAdm Energy Plc	0,175p (-22,22%)	1,19M
PRDPredator Oil & Gas Holdings Plc	5,85p (-20,95%)	5,72M
NTVONativo Resources Plc	0,0021p (10,53%)	844,9M
TRPTower Resources Plc	0,0305p (-1,61%)	507,22M
PREMPremier African Minerals Limited	0,027p (-3,57%)	504,81M
SYMESupply@me Capital Plc	0,003p (-13,04%)	461,39M
ORCPOracle Power Plc	0,016p (-5,88%)	308,68M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Medivir Ab (0GP7)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Medivir Ab

0GP7 Neueste Nachrichten

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Medivir to present at the Carlsquare Equity Research Investor Day

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir to present at the Redeye Life Science Day

Medivir to present at the Erik Penser Bank Company Event

0GP7 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Medivir Ab (0GP7) Börsenkurse

Medivir Ab (0GP7)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Medivir Ab

0GP7 Neueste Nachrichten

0GP7 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen